Collaboration Overview
Merus N.V. and Halozyme Therapeutics have entered a global non-exclusive collaboration and license agreement. This partnership focuses on developing a subcutaneous formulation of petosemtamab, an EGFR x LGR5 bispecific antibody, using Halozyme's ENHANZE® drug delivery technology.
Financial Terms
Under the agreement, Merus will make an upfront payment to Halozyme. Additionally, there are potential future milestone payments related to commercial and sales attainment. Halozyme is also entitled to receive low-mid single digit royalties on net sales of petosemtamab formulated with the ENHANZE® technology during the royalty term.
Target and Potential
Petosemtamab is being developed for subcutaneous administration and targets solid tumor cancers. It has shown promising results in clinical studies and aims to become a first and best in class treatment for head and neck cancer and other indications.
